Obsidian Therapeutics, Inc.: 5%+ holders

As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Obsidian Therapeutics, Inc. The largest reported stake is RA Capital Management, L.P.'s, at 9.7%. 5 filings are on record since August 10, 2026 (Schedule 13G, August 10, 2026).

Atlas Venture Fund X, L.P. also filed stake reports on 5 other companies ↓

Sell to companies like Obsidian Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-10-05 · Reporting person: Paradigm BioCapital Advisors LP · Sole voting: 4,101,576 · Shared voting: 0 · Sole dispositive: 4,101,576 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-05
• Filing 2026-08-11 · Reporting person: Deep Track Capital, LP · Sole voting: 0 · Shared voting: 3,315,605 · Sole dispositive: 0 · Shared dispositive: 3,315,605 · SCHEDULE 13G, 2026-08-11
• Filing 2026-08-10 · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 5,957,103 · Sole dispositive: 0 · Shared dispositive: 5,957,103 · SCHEDULE 13G, 2026-08-10
• Filing 2026-08-10 · Reporting person: Novo Holdings A/S · Sole voting: 3,123,992 · Shared voting: 0 · Sole dispositive: 3,123,992 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-10
• Filing 2026-08-10 · Reporting person: Atlas Venture Fund X, L.P. · Sole voting: 0 · Shared voting: 2,642,587 · Sole dispositive: 0 · Shared dispositive: 2,642,587 · SCHEDULE 13G, 2026-08-10

Obsidian Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2026-08-10. 4 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Obsidian Therapeutics, Inc. and the warning signs.

See Obsidian Therapeutics, Inc.'s free Snapshot Watch Obsidian Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Obsidian Therapeutics, Inc. and the records around it.

Obsidian Therapeutics, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Atlas Venture Fund X, L.P. also filed stake reports on 5 other companies: Kymera Therapeutics, Inc. (Aug 2026), Q32 Bio Inc. (May 2026), GENERATION BIO CO. (May 2026)
• Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), MAPLIGHT THERAPEUTICS, INC. (Jul 2026)
• Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026), Arcellx, Inc. (Aug 2026)

Want the whole picture on Obsidian Therapeutics, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Obsidian Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Obsidian Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   6 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Obsidian Therapeutics, Inc. by CUSIP 67448A106 and gives its principal executive office as 1030 Massachusetts Avenue, Cambridge, MA 02138 (SCHEDULE 13G, 2026-10-05).

What the percentages are based on

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G, 2026-08-10

See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 61,772,876 shares of Common Stock outstanding as of August 10, 2026, as reported by the Issuer in its Form 10-Q filed with the SEC on August 14, 2026.Paradigm BioCapital Advisors LP, SCHEDULE 13G, 2026-10-05

Each of the Fund X Reporting Persons may be deemed to beneficially own 4.3% of the Issuer's outstanding Common Stock. Each of the Opportunity Fund I Reporting Persons may be deemed to beneficially own 1.7% of the Issuer's outstanding Common Stock. Each of the Opportunity Fund II Reporting Persons may be deemed to beneficially own 0.9% of the Issuer's outstanding Common Stock.Atlas Venture Fund X, L.P., SCHEDULE 13G, 2026-08-10

Timeline

Swipe the table sideways to see every column.

Questions about who owns Obsidian Therapeutics, Inc.

Who owns Obsidian Therapeutics, Inc.?

On this page, 4 holders' latest ownership filings report 5% or more of Obsidian Therapeutics, Inc.: RA Capital Management, L.P. (9.7%, Schedule 13G, filed 2026-08-10), Paradigm BioCapital Advisors LP (6.6%, Schedule 13G, filed 2026-10-05), Deep Track Capital, LP (5.37%, Schedule 13G, filed 2026-08-11) and Novo Holdings A/S (5.1%, Schedule 13G, filed 2026-08-10).

Who are the largest shareholders of Obsidian Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Obsidian Therapeutics, Inc. on this page are RA Capital Management, L.P. (9.7%), Paradigm BioCapital Advisors LP (6.6%) and Deep Track Capital, LP (5.37%).

When did RA Capital Management, L.P. buy into Obsidian Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from RA Capital Management, L.P. on this page is the Schedule 13G, filed 2026-08-10, reporting 9.7%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Obsidian Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Obsidian Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Obsidian Therapeutics, Inc. is mentioned again
• Find former Obsidian Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes